STOCK TITAN

Clover Health Investments, Corp. - $CLOV STOCK NEWS

Welcome to our dedicated page for Clover Health Investments news (Ticker: $CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clover Health Investments's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clover Health Investments's position in the market.

Rhea-AI Summary
Clover Health Investments, Corp. (CLOV) granted a restricted stock unit award to a newly hired employee under the 2022 Inducement Award Plan. The employee has the right to receive 902,061 shares of the Company's Class A Common Stock, with vesting over a four-year period. This award aims to attract new talent to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Clover Health Investments, Corp. (NASDAQ: CLOV) aims for Adjusted EBITDA profitability in 2024. CEO Andrew Toy highlights the success in 2023 and plans for 2024, focusing on technology, programs, and expanding offerings. The company targets profitability through improved MA-plan performance and reduced operational spend.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
Rhea-AI Summary
Clover Health Investments, Corp. (NASDAQ: CLOV) released research demonstrating Clover Assistant’s impact on medication adherence in the Medicare Advantage Stars program. The study examined the correlation between PCP use of Clover Assistant and levels of adherence to prescribed medications for common chronic conditions. Dr. Kumar Dharmarajan, Chief Medical Officer of Clover Assistant, highlighted the importance of medication adherence for chronic health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
Rhea-AI Summary
Clover Health Investments, Corp. (Nasdaq: CLOV) announced that its Chief Financial Officer, Scott J. Leffler, will be leaving the company to pursue another professional opportunity. The company has initiated a search for a successor CFO, with Lee A. Shapiro, Chair of the Audit Committee, leading the search committee. The company has engaged a leading executive search firm to assist in finding a new CFO for the next stage of its growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Clover Health Investments, Corp. (NASDAQ: CLOV) announced that its CEO, Andrew Toy, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, at 12:00 p.m. Eastern Time. A live webcast of the presentation will be accessible from Clover Health's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
conferences
-
Rhea-AI Summary
Clover Health Investments, Corp. (NASDAQ: CLOV) has announced its decision to exit the CMS ACO REACH Program at the end of the 2023 performance year. The company will continue to fulfill its obligations for the 2023 performance year, with no impact on its ACO REACH beneficiaries. CEO Andrew Toy stated that the decision was made due to a lack of clear profitability in the ACO REACH business, and the company's focus on profitability in its Medicare Advantage insurance business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
none
Rhea-AI Summary
Clover Health and WellBe Senior Medical have partnered to provide home-based medical care to Georgia residents with complex health conditions, offering in-home visits, personalized care plans, and access to community resources.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.14%
Tags
partnership
-
Rhea-AI Summary
Clover Health Investments, Corp. reported its financial results for the third quarter of 2023. The company's insurance revenue grew by 12% compared to Q3 2022, reaching $301.2 million. The medical care ratio (MCR) for insurance improved to 78.5% from 86.3%. Non-insurance revenue declined by 70% to $176.0 million. The net loss for the quarter was $41.5 million, and adjusted EBITDA loss improved to $5.1 million compared to the same period last year. The revised full-year 2023 guidance reflects an insurance MCR of 81% - 82% and adjusted EBITDA of ($55) million - ($80) million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.14%
Tags
-
Rhea-AI Summary
Clover Health has announced the appointment of Karen Soares as General Counsel. Soares has been with Clover since 2018 and has served in various legal and compliance positions. She will report to Andrew Toy, CEO of Clover.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
Rhea-AI Summary
Clover Health Investments, Corp. to report third quarter 2023 financial results on November 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences earnings
Clover Health Investments, Corp.

Nasdaq:CLOV

CLOV Rankings

CLOV Stock Data

441.83M
375.12M
7.38%
24.46%
8.88%
Direct Health and Medical Insurance Carriers
Finance and Insurance
Link
United States of America
FRANKLIN

About CLOV

clover health (nasdaq: clov) is a physician enablement company focused on seniors who have historically lacked access to affordable, high-quality healthcarewe aim to provide great care, in a sustainable way, by having a business model built around improving medical outcomes while lowering avoidable costs. we do this while taking a holistic approach to understanding the health needs and social risk factors of those under our care. this strategy is underpinned by our proprietary software platform, the clover assistant, which is designed to aggregate patient data from across the health ecosystem to support clinical decision-making by presenting physicians and other providers with real-time, personalized recommendations at the point of care.making care more accessible is at the heart of our business, and we believe patients should have the freedom to choose their doctors. we offer affordable medicare advantage plans with extensive benefits, provide primary care physicians with the clover a